Cooper Alissa J, Rekhtman Natasha, Baine Marina K, Thomas Marie C, Lynch Alia C, Gentzler Ryan D
Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
JTO Clin Res Rep. 2024 Oct 19;5(12):100750. doi: 10.1016/j.jtocrr.2024.100750. eCollection 2024 Dec.
Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy of tarlatamab in other histologies such as DLL3-expressing metastatic pulmonary carcinoid tumor, a clinical entity without many approved management options. Here, we report the case of a patient with metastatic atypical carcinoid tumor which had progressed on multiple previous therapies. Her tumor strongly expressed DLL3 protein and had clinical response to tarlatamab therapy. This case indicates that this novel therapy may be an efficacious option in other pulmonary neuroendocrine cancers.
塔勒妥单抗是一种靶向DLL3的双特异性T细胞衔接器，已迅速成为广泛期小细胞肺癌后线治疗的新标准。对于塔勒妥单抗在其他组织学类型中的疗效，比如表达DLL3的转移性肺类癌肿瘤（一种没有很多获批治疗方案的临床实体），人们了解甚少。在此，我们报告一例转移性非典型类癌肿瘤患者的病例，该患者此前接受多种治疗后病情进展。她的肿瘤强烈表达DLL3蛋白，且对塔勒妥单抗治疗有临床反应。该病例表明，这种新型疗法可能是其他肺神经内分泌癌的一种有效选择。
